Clinical Trial Update: ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating valproic acid to enhance anti-EGFR therapy and prevent/revert resistance in metastatic colorectal cancer; recruitment is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• VALPROIC ACID (Valproic acid)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Colorectal Cancer Metastatic | Phase 2 | Status: RECRUITING